UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) August 8, 2005
Advaxis,
Inc.
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
00028489
|
84
- 1521955
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
212
Carnegie
Center #206, Princeton, NJ
|
08546
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (609)
497-7555
|
(Former
name or former address, if changed since last
report.)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01. Other
Events
On
August
8, 2005, the Registrant announced that its GMP clinical materials had passed
quality control release and is available for use in Advaxis’ Phase I/II clinical
trial of Lovaxin C in advance cervical cancer patients. See Registrant’s press
release attached hereto as Exhibit 99.1.
Item
9.01. Financial
Statements and Exhibits
a) Not
applicable.
b) Not
applicable.
c) Exhibits
99.1. |
Press
Release, dated August 8, 2005
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August
8,
2005
|
|
|
|
ADVAXIS,
INC. |
|
|
|
|
By: |
/s/
J. Todd Derbin |
|
Name:
J.
Todd Derbin
Title:
President
and Chief
Executive
Officer
|
|
|